

Toon Van Gorp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3149008/publications.pdf>

Version: 2024-02-01

137
papers

4,688
citations

101496
36
h-index

114418
63
g-index

141
all docs

141
docs citations

141
times ranked

5630
citing authors

#	ARTICLE	IF	CITATIONS
1	Incomplete surgical staging in clinical early-stage ovarian cancer: guidelines versus daily practice. Surgery Open Science, 2022, 7, 6-11.	0.5	1
2	Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group. International Journal of Gynecological Cancer, 2022, 32, 753-760.	1.2	3
3	Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study. Cancers, 2022, 14, 1780.	1.7	4
4	Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer. Gynecologic Oncology, 2022, 165, 14-22.	0.6	14
5	tRNAGlyGCC-Derived Internal Fragment (i-tRF-GlyGCC) in Ovarian Cancer Treatment Outcome and Progression. Cancers, 2022, 14, 24.	1.7	25
6	TRP channel expression correlates with the epithelialâ€mesenchymal transition and high-risk endometrial carcinoma. Cellular and Molecular Life Sciences, 2022, 79, 1.	2.4	9
7	Ovarian cancer ascites induces skeletal muscle wasting <i>in vitro</i> and reflects sarcopenia in patients. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 311-324.	2.9	8
8	Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer. Npj Genomic Medicine, 2022, 7, 30.	1.7	4
9	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENAâ€MONO/GOG-3020/ENGOT-ov45). Journal of Clinical Oncology, 2022, 40, 3952-3964.	0.8	125
10	TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab versus best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.. Journal of Clinical Oncology, 2022, 40, TPS5614-TPS5614.	0.8	2
11	Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRI±) expression: Characterization of antitumor activity in the SORAYA study.. Journal of Clinical Oncology, 2022, 40, 5512-5512.	0.8	15
12	ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigatorâ€™s choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer.. Journal of Clinical Oncology, 2022, 40, TPS5620-TPS5620.	0.8	2
13	Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.. Journal of Clinical Oncology, 2022, 40, 5511-5511.	0.8	6
14	Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor ± (FRI±)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials.. Journal of Clinical Oncology, 2022, 40, 5574-5574.	0.8	2
15	Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2022, 40, LBA5503-LBA5503.	0.8	4
16	SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. Journal of Clinical Oncology, 2021, 39, TPS5610-TPS5610.	0.8	6
17	Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2021, 39, TPS5607-TPS5607.	0.8	5
18	High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. Genome Medicine, 2021, 13, 111.	3.6	70

#	ARTICLE	IF	CITATIONS
19	Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria. <i>Gynecologic Oncology</i> , 2021, 162, 539-545.	0.6	7
20	Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study. <i>Gynecologic Oncology</i> , 2021, 162, 694-701.	0.6	9
21	Experience with PlasmaJet [®] in debulking surgery in 87 patients with advanced-stage ovarian cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1109-1114.	0.8	6
22	Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer: real-world evidence from a large single-centre cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1041-1048.	1.2	1
23	Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?. <i>Journal of Ovarian Research</i> , 2021, 14, 132.	1.3	15
24	O013/#573â€¦Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (R/MCC): phase 1B/2 engot-CX8/GOG-3024/innovaTV 205 study dose-escalation results. , 2021, , .		0
25	Association of a Combined Cancer Exhaustion Score with Circulating Tumor Cells and Outcome in Ovarian Cancerâ€”A Study of the OVCAD Consortium. <i>Cancers</i> , 2021, 13, 5865.	1.7	3
26	The LACC Trial and Minimally Invasive Surgery in Cervical Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 462-463.	0.3	27
27	What do we need to know about anatomy in gynaecology: A Delphi consensus study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 245, 56-63.	0.5	8
28	Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. <i>Gynecologic Oncology</i> , 2020, 159, 811-819.	0.6	8
29	No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study. <i>Gynecologic Oncology</i> , 2020, 159, 706-711.	0.6	12
30	Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D. <i>Gynecologic Oncology</i> , 2020, 157, 245-251.	0.6	24
31	Short-term surgical complications after radical hysterectomyâ€”A nationwide cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 925-932.	1.3	11
32	Para-aortic lymph node surgical staging in locally-advanced cervical cancer: comparison between robotic versus conventional laparoscopy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 466-472.	1.2	8
33	MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigatorâ€™s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FR α) expression.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6103-TPS6103.	0.8	6
34	Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1165-1174.	2.9	108
35	Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review. <i>Journal of Ovarian Research</i> , 2019, 12, 105.	1.3	25
36	Assessment of parametrial invasion of cervical carcinoma, the role of T2-weighted MRI and diffusion weighted imaging with or without fusion. <i>Clinical Radiology</i> , 2019, 74, 790-796.	0.5	7

#	ARTICLE	IF	CITATIONS
37	Trends in incidence, treatment and survival of borderline ovarian tumors in the Netherlands: a nationwide analysis. <i>Acta Oncol</i> ³ <i>gica</i> , 2019, 58, 983-989.	0.8	18
38	EP877â€¦Intestinal (sub)obstruction in ovarian cancer patients: management, complications and survival. , 2019, , .		0
39	Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5507-5507.	0.8	36
40	Medical studentsâ€™ perspective on training in anatomy. <i>Annals of Anatomy</i> , 2018, 217, 60-65.	1.0	25
41	Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. <i>Gynecologic Oncology</i> , 2018, 148, 56-61.	0.6	18
42	Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer. <i>European Journal of Cancer</i> , 2018, 100, 55-64.	1.3	5
43	Positron emission tomography-magnetic resonance imaging (PET-MRI) for response assessment after radiation therapy of cervical carcinoma: a pilot study. <i>EJNMMI Research</i> , 2018, 8, 1.	1.1	33
44	Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 613-621.	0.8	103
45	The influence of sarcopenia on survival and surgical complications in ovarian cancer patients undergoing primary debulking surgery. <i>European Journal of Surgical Oncology</i> , 2017, 43, 717-724.	0.5	81
46	Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 630-638.	2.9	144
47	Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial. <i>BMC Cancer</i> , 2017, 17, 110.	1.1	18
48	Simple Rules, Not So Simple: The Use of International Ovarian Tumor Analysis (IOTA) Terminology and Simple Rules in Inexperienced Hands in a Prospective Multicenter Cohort Study. <i>Ultraschall in Der Medizin</i> , 2017, 38, 633-641.	0.8	15
49	Correspondence: Premature Stop of the SOCceR Trial, a Multicenter Randomized Controlled Trial on Secondary Cytoreductive Surgery. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 2-2.	1.2	10
50	Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 449-456.	0.6	15
51	Comparison of Intraoperative ¹³ -Probe Imaging and Postoperative SPECT/CT in Detection of Sentinel Nodes Related to the Ovary. <i>Journal of Nuclear Medicine</i> , 2017, 58, 243-245.	2.8	14
52	Estimating risk of malignancy in adnexal masses: external validation of the <scp>ADNEX</scp> model and comparison with other frequently used ultrasound methods. <i>Ultrasound in Obstetrics and Gynecology</i> , 2017, 49, 784-792.	0.9	71
53	Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e7.	1.0	28
54	Predictive criteria for MRI-based evaluation of response both during and after radiotherapy for cervical cancer. <i>Journal of Contemporary Brachytherapy</i> , 2016, 3, 181-188.	0.4	10

#	ARTICLE	IF	CITATIONS
55	Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 458-466.	2.9	161
56	The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer. <i>European Journal of Cancer</i> , 2016, 66, 83-90.	1.3	42
57	TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2016, 16, 132.	1.1	14
58	Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: An external validation study of three models using computed tomography. <i>Gynecologic Oncology</i> , 2016, 140, 22-28.	0.6	21
59	Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2016, 58, 17-29.	1.3	172
60	Surgery for Recurrent Epithelial Ovarian Cancer in the Netherlands. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 268-275.	1.2	18
61	Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1405-1414.	1.2	53
62	Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 253-255.	0.2	0
63	Consecutive magnetic resonance imaging during brachytherapy for cervical carcinoma: predictive value of volume measurements with respect to persistent disease and prognosis. <i>Radiation Oncology</i> , 2015, 10, 252.	1.2	5
64	Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass. <i>Journal of the National Cancer Institute</i> , 2015, 107, 322.	3.0	16
65	Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 527-546.	1.5	48
66	External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 137, 210-215.	0.6	28
67	Investigating the performance and cost-effectiveness of the simple ultrasound-based rules compared to the risk of malignancy index in the diagnosis of ovarian cancer (SUBSONiC-study): protocol of a prospective multicenter cohort study in the Netherlands. <i>BMC Cancer</i> , 2015, 15, 482.	1.1	9
68	Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?. <i>Ultrasound in Obstetrics and Gynecology</i> , 2014, 43, 89-97.	0.9	28
69	External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2014, 110, 42-48.	2.9	25
70	Angiosarcomas of Primary Gynecologic Origin: A Clinicopathologic Review and Quantitative Analysis of Survival. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 4-12.	1.2	41
71	Prognostic Value of Serum HE4 Levels and Risk of Ovarian Malignancy Algorithm Scores at the Time of Ovarian Cancer Diagnosis. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1173-1180.	1.2	22
72	Aggressive Behavior and Poor Prognosis of Endometrial Stromal Sarcomas With YWHAE-FAM22 Rearrangement Indicate the Clinical Importance to Recognize This Subset. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1616-1622.	1.2	23

#	ARTICLE	IF	CITATIONS
73	The majority of metachronous CIN1 and CIN3 lesions are caused by different human papillomavirus genotypes, indicating that the presence of CIN1 seems not to determine the risk for subsequent detection of CIN3. Human Pathology, 2014, 45, 221-226.	1.1	6
74	Mucinous borderline tumours of the ovary and the appendix: A retrospective study and overview of the literature. Gynecologic Oncology, 2014, 133, 155-158.	0.6	30
75	Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. BMC Cancer, 2014, 14, 22.	1.1	37
76	The Detection of Sentinel Nodes in Ovarian Cancer: A Feasibility Study. Journal of Nuclear Medicine, 2014, 55, 1799-1804.	2.8	45
77	A family history questionnaire improves detection of women at risk for hereditary gynecologic cancer: a pilot study. Familial Cancer, 2014, 13, 469-475.	0.9	8
78	Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium. Journal of Ovarian Research, 2014, 7, 49.	1.3	21
79	Lymph-node metastasis in stage I and II sex cord stromal and malignant germ cell tumours of the ovary: A systematic review. Gynecologic Oncology, 2014, 133, 124-127.	0.6	20
80	Sentinel node in ovarian cancer: study protocol for a phase 1 study. Trials, 2013, 14, 47.	0.7	7
81	A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium. BMC Cancer, 2013, 13, 178.	1.1	29
82	Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumors using biomarkers or the ROMA algorithm. Gynecologic Oncology, 2013, 130, 398-399.	0.6	9
83	The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma – Analysis of patient data in the prospective OVCAD study. Gynecologic Oncology, 2013, 131, 15-20.	0.6	99
84	Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – A study of the OVCAD consortium. Gynecologic Oncology, 2013, 128, 15-21.	0.6	107
85	The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: Survey among Dutch gynecologists and medical oncologists. Gynecologic Oncology, 2013, 131, 561-566.	0.6	5
86	Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients. Gynecologic Oncology, 2013, 128, 245-251.	0.6	56
87	The value of imaging of the lungs in the diagnostic workup of patients with endometrial cancer. Gynecologic Oncology, 2013, 131, 147-150.	0.6	5
88	A comparison between an ultrasound based prediction model (LR2) and the Risk of Ovarian Malignancy Algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass. Gynecologic Oncology, 2013, 129, 377-383.	0.6	47
89	Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium – OVCAD. International Journal of Gynecological Cancer, 2013, 23, 268-275.	1.2	46
90	Overexpression of 17 β -Hydroxysteroid Dehydrogenase Type 1 Increases the Exposure of Endometrial Cancer to 17 β -Estradiol. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E591-E601.	1.8	62

#	ARTICLE	IF	CITATIONS
91	Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV: Analysis of the OVCAD Data. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 380-385.	1.2	91
92	Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. <i>European Journal of Cancer</i> , 2012, 48, 1649-1656.	1.3	104
93	Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium. <i>Molecular Cancer</i> , 2012, 11, 69.	7.9	35
94	Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS. <i>Proteome Science</i> , 2012, 10, 41.	0.7	9
95	Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study. <i>BMC Cancer</i> , 2012, 12, 31.	1.1	48
96	Gynecologic Oncology Training Systems in Europe. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1500-1506.	1.2	16
97	The utility of proteomics in gynecologic cancers. <i>Current Opinion in Obstetrics and Gynecology</i> , 2011, 23, 3-7.	0.9	17
98	Performance of the American College of Obstetricians and Gynecologists' Ovarian Tumor Referral Guidelines With a Multivariate Index Assay. <i>Obstetrics and Gynecology</i> , 2011, 118, 1179-1181.	1.2	9
99	Lymph node density as a surrogate marker for positive lymph nodes. <i>British Journal of Cancer</i> , 2011, 104, 221-222.	2.9	1
100	HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. <i>British Journal of Cancer</i> , 2011, 104, 863-870.	2.9	270
101	Discovery of novel monoclonal antibodies (MC1–MC6) to detect ovarian cancer in serum and differentiate it from benign tumors. <i>Gynecologic Oncology</i> , 2011, 120, S67.	0.6	0
102	Re: Post-coital vaginal douching is risky for non-regression of low-grade squamous intraepithelial lesion of the cervix. <i>Gynecologic Oncology</i> , 2011, 122, 202-203.	0.6	1
103	Lymph node metastasis in stages I and II ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2011, 123, 610-614.	0.6	145
104	Reply: The performance of the risk of ovarian malignancy algorithm. <i>British Journal of Cancer</i> , 2011, 105, 187-188.	2.9	0
105	Proteomic Analysis of Laser Microdissected Ovarian Cancer Tissue with SELDI-TOF MS. <i>Methods in Molecular Biology</i> , 2011, 755, 155-163.	0.4	9
106	The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 542-551.	1.2	9
107	The Use of Lymph Vessel Markers to Predict Endometrial Cancer Outcome. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 363-367.	1.2	13
108	Diaphragmatic surgery during primary debulking in 89 patients with stage III–IV epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 489-496.	0.6	31

#	ARTICLE	IF	CITATIONS
109	The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells. <i>Gynecologic Oncology</i> , 2010, 118, 64-68.	0.6	5
110	Application of proteomics in ovarian cancer: Which sample should be used?. <i>Gynecologic Oncology</i> , 2009, 115, 497-503.	0.6	13
111	0139 Why 28% of ER-negative/PR-negative breast cancer (BC) patients did not get chemotherapy (CT). <i>Breast</i> , 2009, 18, S53.	0.9	0
112	Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 181-187.	1.1	76
113	Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of BRCA-Related Ovarian Cancer Patients?. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1501-1504.	1.2	7
114	Role of Diaphragmatic Surgery in 69 Patients With Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 481-481.	1.2	11
115	Robotic retroperitoneal lower para-aortic lymphadenectomy in cervical carcinoma: First report on the technique used in 5 patients. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2008, 87, 783-787.	1.3	70
116	Role of diaphragmatic surgery in 69 patients with ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 363-368.	1.2	35
117	Timing of debulking surgery in advanced ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 11-19.	1.2	79
118	Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation. <i>BMC Cancer</i> , 2008, 8, 18.	1.1	13
119	A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis. <i>Breast Cancer Research</i> , 2008, 10, 109.	2.2	13
120	Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View. <i>Oncologist</i> , 2008, 13, 410-414.	1.9	23
121	Improving outcome in the first-line management of advanced ovarian cancer. <i>European Journal of Cancer</i> , Supplement, 2007, 5, 23-28.	2.2	3
122	Management of Borderline Ovarian Neoplasms. <i>Journal of Clinical Oncology</i> , 2007, 25, 2928-2937.	0.8	174
123	A new prognostic model for FIGO stage 1 epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 104, 607-611.	0.6	29
124	The â€œLeuvenâ€ dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 106, 354-361.	0.6	37
125	Chemotherapy for recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2007, 107, S113-S118.	0.6	47
126	Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: safety, recurrence, and long-term outcome. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 196, 248.e1-248.e8.	0.7	87

#	ARTICLE	IF	CITATIONS
127	The role of Neoadjuvant Chemotherapy versus Primary Surgery in the Management of Stage III Ovarian Cancer. , 2007, 134, 387-402.		6
128	The management of borderline tumours of the ovary. Current Opinion in Oncology, 2006, 18, 488-493.	1.1	32
129	Predicting the clinical behavior of ovarian cancer from gene expression profiles. International Journal of Gynecological Cancer, 2006, 16, 147-151.	1.2	23
130	Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant. International Journal of Gynecological Cancer, 2006, 16, 524-526.	1.2	8
131	Methodology in plasma proteomic pattern experiments. International Journal of Gynecological Cancer, 2006, 16, 1951-1952.	1.2	0
132	Ovarian cancer. Critical Reviews in Oncology/Hematology, 2006, 60, 159-179.	2.0	186
133	Molecular profiling of platinum resistant ovarian cancer: Use of the model in clinical practice. International Journal of Cancer, 2006, 119, 1511-1511.	2.3	1
134	The position of neoadjuvant chemotherapy within the treatment of ovarian cancer. Minerva Ginecologica, 2006, 58, 393-403.	0.8	1
135	Independent Test Set Performance in the Prediction of Early Relapse in Ovarian Cancer with Gene Expression Profiles. Clinical Cancer Research, 2005, 11, 7958-7959.	3.2	2
136	Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2004, 18, 349-371.	1.4	257
137	Endometrial safety of hormone replacement therapy: review of literature. Maturitas, 2002, 42, 93-104.	1.0	41